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Background: Fragile X syndrome (FXS) is caused by the absence of the mRNA-binding protein Fragile X mental
retardation protein (FMRP), encoded by the Fmr1 gene. Overactive signaling by group 1 metabotropic glutamate
receptor (Grp1 mGluR) could contribute to slowed synaptic development and other symptoms of FXS. Our previous
study has identified that facilitation of synaptic long-term potentiation (LTP) by D1 receptor is impaired in Fmr1
knockout (KO) mice. However, the contribution of Grp1 mGluR to the facilitation of synaptic plasticity by D1
receptor stimulation in the prefrontal cortex has been less extensively studied.
Results: Here we demonstrated that DL-AP3, a Grp1 mGluR antagonist, rescued LTP facilitation by D1 receptor
agonist SKF81297 in Fmr1KO mice. Grp1 mGluR inhibition restored the GluR1-subtype AMPA receptors surface
insertion by D1 activation in the cultured Fmr1KO neurons. Simultaneous treatment of Grp1 mGluR antagonist with
D1 agonist recovered the D1 receptor signaling by reversing the subcellular redistribution of G protein-coupled
receptor kinase 2 (GRK2) in the Fmr1KO neurons. Treatment of SKF81297 alone failed to increase the
phosphorylation of NR2B-containing N-methyl D-aspartate receptors (NMDARs) at Tyr-1472 (p-NR2B-Tyr1472) in the
cultures from KO mice. However, simultaneous treatment of DL-AP3 could rescue the level of p-NR2B-Tyr1472 by
SKF81297 in the cultures from KO mice. Furthermore, behavioral tests indicated that simultaneous treatment of
Grp1 mGluR antagonist with D1 agonist inhibited hyperactivity and improved the learning ability in the Fmr1KO
mice.
Conclusion: The findings demonstrate that mGluR1 inhibition is a useful strategy to recover D1 receptor signaling
in the Fmr1KO mice, and combination of Grp1 mGluR antagonist and D1 agonist is a potential drug therapy for the
FXS.
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Fragile X syndrome is the most common form of inher-
ited mental retardation, characterized by moderate to se-
vere mental retardation, attention deficits, and anxiety.
This disease results from the expansion of a trinucleo-
tide repeat (CGG) within the X-linked FMR1 gene [1-4].
As a result of this expansion, the product of the FMR1* Correspondence: minggao@fmmu.edu.cn; mgzhao@hotmail.com
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reproduction in any medium, provided the orgene, fragile X mental retardation protein (FMRP), is not
expressed [1,5,6]. FMRP is a mRNA binding protein that
is associated with polyribosomes and is thought to be
involved in the translational efficiency and/or trafficking
of certain mRNAs [7,8].
Recent progress in the study of the mouse model of Fra-
gile X has led to a theory that the absence of FMRP leads
to misregulation of protein synthesis at the synapse that
occurs in response to mGluR activity [9,10]. An extension
of this theory is that modulation of mGluR activity with
antagonists should reverse phenotypes attributable to loss
of FMRP function. Exaggerated translation linked to groupThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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mGluRs, could contribute to slowed synaptic development
and other symptoms of FXS [9,10]. This is supported by
the observations that mGluR-induced long-term depres-
sion is increased in the hippocampus of Fmr1 knock-out
(KO) mice [9].
A myriad of studies have defined synaptic plasticity
deficits in Fmr1 KO mice [11-15]. Long-term potenti-
ation (LTP), a type of long lasting synaptic plasticity, is
believed to be involved in learning and memory [16,17].
Prefrontal cortex (PFC)-associated molecular, cellular,
and behavioral abnormality in Fmr1 KO mouse is a use-
ful model for testing the efficacy of therapeutic strategies
aimed at treating the cognitive impairments in FXS [18].
Our previous studies show that long-term potentiation
(LTP) is completely abolished in the PFC [11]. Dopamine
(DA) in the prefrontal cortex (PFC) plays a critical role in
cognitive functions and neuropsychiatric pathology
[19-23]. It is well known that DA functions in its tar-
get cells through five subtypes of DA receptors (D1-5)
[22,24,25]. Recent studies have been carried out by nu-
merous groups to investigate the cellular mechanism for
DA modulation in PFC neurons [21,22,26-30]. Our recent
study reveals that FMRP contributes to dopamine modu-
lation of AMPA GluR1 receptor synaptic insertion and
dopaminergic facilitation of LTP [31]. These findings pro-
vide the evidence that FMRP acts as a key messenger for
DA receptor-mediated modulation in forebrain neurons.
Given the enhanced mGluR activity in the brains of
Fmr1 KO mice, we explored the possibility that mGluR1
misregulation might act on dopamine modulation in the
prefrontal synaptic plasticity. Here we showed that
mGluR1 inhibition rescued LTP facilitation by D1 recep-
tor in Fmr1 KO mice, without having effects on basal
glutamatergic synaptic transmission.
Results
Grp1 mGluR antagonist rescues LTP facilitation by D1
activation in Fmr1 KO mice
The PFC, including its cingulate region, plays an im-
portant role in learning and memory, drug addiction,
and pain [11,32,33]. First, we performed whole-cell
patch-clamp recordings in visually identified pyramidal
neurons in layers II–III of cingulate region of PFC slices.
LTP was induced by pairing presynaptic stimulation with
postsynaptic depolarization. The pairing training pro-
duced a significant, long-lasting potentiation of synaptic
responses in WT mice (146.5%±6.7%, n= 12 slices/5 mice;
p< 0.01 versus baseline; Figure 1A), but not in KO mice
(108.9%±5.4%, n =9 slices/4 mice; p> 0.05 versus pairing
training only; Figure 1A). Since Grp1 mGluR-LTD is exag-
gerated in the Fmr1 KO mouse, we next examined the
effects of mGluR1 antagonist on LTP induction in the
PFC. It has been reported that high dose of mGluR1antagonist, DL-2-amino-3-phosphonopropionic acid (DL-
AP3, 300 μM) or (+)-alpha-methyl-4-carboxyphenylglycine
(MCPG, 500 μM), reduced homosynaptic LTP in the
hippocampus [34,35]. In the present study, the slices were
incubated with mGluR1 antagonist DL-AP3 at low dose of
10 μM at least for 30 min before the LTP induction was
performed. At the concentration of 10 μM, DL-AP3 did
not alter the amplitude of LTP as compared to the pairing
training only in the WT (145.7%±7.9%, n=9 slices/3 mice;
p< 0.05 versus pairing training only; Figure 1B) and KO
(108.3%±6.2%, n=11 slices/5 mice; p< 0.05 versus pairing
training only; Figure 1B) mice. We next paired D1 agonist
application with an LTP induction protocol. Bath applica-
tion of SKF81297 (5 μM) for 10 min paired with the LTP
induction protocol significantly enhanced the amplitude of
LTP (174.3%±9.4%, n=8 slices/3 mice; p< 0.01 versus
pairing training only; Figure 1C), suggesting that D1 recep-
tor activation can facilitate LTP induction in the WT mice.
However, in Fmr1 KO mice SKF81297 pairing training
could not induce LTP (106.2%±6.2%, n=11 slices/5 mice;
p> 0.05 versus baseline responses; Figure 1C), demonstrat-
ing that dopaminergic facilitation of LTP is impaired in
Fmr1 KO mice.
Next, D1 agonist and mGluR1 antagonist were applied
simultaneously to detect their synergistic effects on the
LTP induction. Bath application of SKF81297 (5 μM)
and DL-AP3 (10 μM) for 10 min induced a significant
LTP (178.5%± 8.1%, n = 10 slices/3 mice; p< 0.01 versus
pairing training only; Figure 1D). Further comparison
analysis found that the amplitude of the LTP was similar
to the LTP induced by SKF81297 (5 μM) alone in the
WT mice (p> 0.05 as compared to the SKF81297 +DL-
AP3). However, simultaneous application of DL-AP3
(10 μM) markedly rescued the LTP induction by
SKF81297 in the Fmr1 KO mice (137.6% ± 6.5%, n = 12
slices/4 mice; p< 0.05 versus SKF81297 alone; Figure 1D
and 1H). Additional D1 receptor antagonist SCH23390
(10 μM) for 10 min prior to, and during electrical stimula-
tion totally blocked the LTP which was rescued by syner-
gistic application of SKF81297 and DL-AP3 in the KO
mice (102.8%±6.5%, n = 13 slices/4 mice; p> 0.05 versus
baseline; Figure 1E and 1H).
SKF81297 (5 mM, 30 min) or DL-AP3 (10 μM, 30 min)
had no effect on basal synaptic responses (Figure 1F and
1G). Thesis data indicate that lower dose of DL-AP3
(10 μM) dose not alter the LTP induction in the Fmr1
WT and KO mice; however, it rescues the LTP facilitation
of D1 receptor activation in the Fmr1 KO mice.
Adenylyl cyclase agonist rescues LTP facilitation by D1
activation in Fmr1 KO mice
In our previous study, we found that D1 receptor signal-
ing is impaired, i.e., the increase in cAMP caused by
SKF81297 is attenuated, accompanied by D1 receptor
Figure 1 Rescue of D1-induced LTP by DL-AP3 in the Fmr1 KO mice. (A) The pairing training produced a significant, long-lasting
potentiation of synaptic responses in Fmr1 WT mice (n = 12 slices/5 mice), but not in Fmr1 KO mice (n = 9 slices/4 mice); (B) DL-AP3 (10 μM) did
not alter the amplitude of LTP in Fmr1 WT mice (n = 9 slices/3 mice). DL-AP3 (10 μM) failed to induce LTP in Fmr1 KO mice (n = 11 slices/5
mice). (C) SKF81297 (5μM) facilitated LTP induction in Fmr1 WT mice (n = 8 slices/3 mice), but failed to induce LTP in Fmr1 KO mice (n = 11
slices/5 mice). (D) Bath application of SKF81297 (5 μM) and DL-AP3 (10 μM) induced LTP in Fmr1 WT mice (n = 10 slices/3 mice) (n = 10 slices/3
mice) and markedly rescued the LTP induction by SKF81297 in the Fmr1 KO mice (n = 12 slices/4 mice). (E) SCH23390 (10 μM) blocked the LTP
by synergistic application of SKF81297 and DL-AP3 in the KO mice (n = 13 slices/4 mice). (F and G) SKF81297 (5 μM, 30 min) or DL-AP3 (10 μM,
30 min) had no effect on basal synaptic responses without pairing training (n = 8) in the Fmr1 WT and KO mice. (H) Summary of the effects of
DL-AP3 or/and SKF81297 on the LTP induction. *p < 0.05, **p < 0.01 compared with WT; #p < 0.05 compared with control; &&p < 0.01
compared with SKF81297 + DL-AP3 in WT mice; @p < 0.05 compared with SKF81297 + DL-AP3 in KO mice.
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KO mice. To detect whether or not the increase of
cAMP could mimic the function of D1 receptor, the ade-
nylyl cyclase activator, forskolin, was used. Many studies
have used forskolin to stimulate AMPAR trafficking and
induce chemical LTP [36-39]. In the present study, un-
like in the hippocampus, LTP was not induced during
the application of forskolin (10 μM), which was not
paired with the electrical stimulation in the ACC, i.e., no
chemical LTP was induced in the ACC (101.9%± 3.6%,n= 9 slices/4 mice; p> 0.05 versus baseline before perfu-
sion of forskolin; Figure 2A). The amplitude of LTP is
similar to that of the control when the forskolin was
paired with the electrical stimulation in the Fmr1 WT
mice (155.8%± 3.5%, n = 12 slices/4 mice; p> 0.05 versus
pairing training only; Figure 2B). Combining forskolin
with DL-AP3 did not result in an increase in the ampli-
tude of LTP compared with the case, in which the forsko-
lin alone was used in the Fmr1 WT mice (159.4%±3.4%,
n = 10 slices/4 mice; p> 0.05 versus forskolin alone;
Figure 2 Synergistic effects of DL-AP3 and forskolin on the LTP induction in the Fmr1 KO mice. (A) Forskolin (10 μM) did not induce
chemical LTP in the ACC without pairing training (n = 9 slices/4 mice). (B) Forskolin (10 μM) failed to induce LTP in the Fmr1 KO mice (n = 8
slices/4 mice). LTP in the presence of forskolin (10 μM) is similar to the control in the Fmr1 WT mice (n = 12 slices/4 mice). (C) Bath application of
SKF81297 (5μM) and DL-AP3 (10 μM) induced similar LTP as control in Fmr1 WT mice (n = 10 slices/4 mice). Combining forskolin with DL-AP3
partially rescued LTP in the Fmr1 KO mice (n = 11 slices/4 mice). (D) LTP facilitation by SKF81297 (5 μM) was blocked by AP5 (50 μM) (n = 10
slices/3 mice). (E) LTP facilitation by SKF81297 (5 μM) was blocked by 10 mM BAPTA in the pipette solution (n = 10 slices/3 mice). (F) Summary
of the effects of forskolin or/and DL-AP3 on the LTP induction. *p < 0.05, **p < 0.01 compared with WT; &p < 0.05 compared with forskolin in
KO mice.
Xu et al. Molecular Neurodegeneration 2012, 7:24 Page 4 of 14
http://www.molecularneurodegeneration.com/content/7/1/24Figure 2C). Forskolin (10 μM) paired with the electrical
stimulation was unable to induce LTP in the Fmr1 WT
mice (107.2%±3.2%, n = 8 slices/4 mice; p> 0.05 versus
pairing training only; Figure 2B). However, combining for-
skolin with DL-AP3 partially rescued LTP in the Fmr1 KO
mice, even if the amplitude was only 118%±2.8% of the
base line (n= 11 slices/4 mice; p< 0.05 versus DL-AP3
alone; Figures 2C and 2F).
To determine whether or not dopaminergic modula-
tion of LTP required NMDAR activation, we applied a
selective NMDAR antagonist, AP5 (50 μM), and found
that LTP facilitation by SKF81297 (5 μM) was com-
pletely blocked (Figure 2D). Similarly, LTP was abolished
by 10 mM BAPTA in the pipette solution (Figure 2E),
indicating that dopaminergic modulation of LTP
depended on the activation of NMDARs and elevated
postsynaptic Ca2+ concentrations.
Grp1 mGluRs modulate plasticity by a postsynaptic
mechanism
In the different regions of the hippocampus, both presynap-
tic and postsynaptic mechanisms have been proposed to
contribute to the expression of LTP [40]. To determinewhether presynaptic and/or postsynaptic mechanisms are
involved in Grp1 mGluRs modulation of LTP, we measured
paired-pulse facilitation (PPF) in the ACC. PPF is a
phenomenon by which a second synaptic stimulation of
equal magnitude evokes a larger synaptic response than the
first, and has been used as a tool to implicate presynaptic
probability of transmitter release [41,42]. As shown in
Figure 3, PPF induced at five different intervals did
not differ in WT (Figure 3A) and Fmr1 KO mice
(Figure 3B) in the presence of DL-AP3 (10 μM) or/and
SKF81297 (5 μM) in the ACC. The data suggest that pre-
synaptic mechanisms do not seem to be involved in the
Grp1 mGluRs modulation of LTP.
No changing of basal glutamatergic synaptic transmission
by Grp1 mGluRs inhibition
To determine whether Grp1 mGluRs inhibition affects
basal glutamatergic synaptic transmission in the ACC,
we measured the miniature AMPA receptor-mediated
EPSCs (mEPSCs). As shown in Figure 4, no significant
alteration was detected in the AMPA receptor-mediated
mEPSCs frequency and amplitude among the control,
DL-AP3 (10 μM) or/and SKF81297 (5 μM) treated slices
Figure 3 Postsynaptic mechanisms underlying the LTP facilitation by Grp1 mGluRs inhibition. Paired-pulse facilitation (the ratio of EPSC2/
EPSC1) was recorded with intervals of 35, 50, 75, 100, and 150 ms. (A) Representative traces of PPF with an interval of 50 ms recorded in the Fmr1
WT mice ACC. (B) PPF was not changed at each interval in Fmr1 WT mice after perfusion of DL-AP3 (10 μM) or/and SKF81297 (5 μM) (n = 6 slices/
3 mice in each group). (C) Representative traces of PPF with an interval of 50 ms recorded in the Fmr1 KO mice ACC. (D) PPF was not changed
at each interval in Fmr1 KO mice after perfusion of DL-AP3 (10 μM) or/and SKF81297 (5 μM) (n = 6 slices/3 mice in each group).
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Figure 4). Results indicate that by Grp1 mGluRs inhib-
ition and activation of D1 receptor have no effect on the
basal excitatory synaptic transmission in the ACC.
Inhibition of Grp1 mGluRs rescues expression of GluR1 by
D1 receptor
To determine the synergistic effect on the AMPA receptor
expression and surface insertion, we treated cultured PFC
neurons with the D1 receptor agonists SKF81297 and
Grp1 mGluRs antagonist DL-AP3. SKF81297 (5 μM)
alone or combining with DL-AP3 (10 μM) increased the
total expression levels of GluR1 in the cultures from Fmr1
WT mice (Figure 5A). However, neither SKF81297 nor
DL-AP3 affected the total expression levels of GluR1 in
cultures from Fmr1 KO mice (Figure 5B). To further in-
vestigate the signaling involved in the synaptic plasticity,
we tested the effects of DL-AP3 or/and SKF81297 on
AMPA receptor GluR1 subunits surface trafficking in cul-
tured PFC neurons. Surface expression of GluR1 was
increased after treatment with SKF81297 (5 μM) alone or
combining with DL-AP3 (10 μM) in the cultures from
Fmr1 WT mice (Figure 5C). Contrast to the unchanged
total levels of GluR1, surface expression of GluR1 was
increased after simultaneous treatment of SKF81297
(5 μM) and DL-AP3 (10 μM) in the cultures from Fmr1
KO mice (Figure 5D). This finding demonstrates thatinhibition of Grp1 mGluRs can rescue the surface expres-
sion of AMPA GluR1 receptors by D1 receptor in Fmr1
KO PFC neurons.
Furthermore, the synergistic effects of DL-AP3 and for-
skolin on AMPA receptor GluR1 subunits surface traffick-
ing were detected in cultured PFC neurons. Forskolin
(10 μM) alone or combined with DL-AP3 (10 μM)
increased the total expression levels of GluR1 in the cul-
tures from Fmr1 WT mice (Figure 5E). However, neither
forskolin (10 μM) nor DL-AP3 affected the total expres-
sion levels of GluR1 in cultures from Fmr1 KO mice
(Figure 5E). The surface expressions of GluR1 in the cul-
tures from Fmr1 WT mice increased after treatment with
forskolin (10 μM) alone and combined with DL-AP3
(10 μM) (Figure 5F). In contrast with the unchanged total
levels of GluR1, surface expressions of GluR1 in the cul-
tures from Fmr1 KO mice increased after simultaneous
treatment of forskolin (10 μM) and DL-AP3 (10 μM)
(Figure 5F). This finding demonstrated the synergistic
effects on the surface expressions of AMPA GluR1 recep-
tors in Fmr1 KO PFC neurons resulting from the inhib-
ition of Grp1 mGluRs and activation of adenylyl cyclase.
Inhibition of Grp1 mGluRs reverses redistribution of GRK2
Our previous study shows that D1 receptor signaling is
impaired, accompanied by D1 receptor hyperphosphorylation
at serine sites and subcellular redistribution of G protein-
Figure 4 Basal glutamatergic synaptic transmission in the ACC. (A) AMPA receptor-mediated mEPSCs recorded in the ACC neurons at a
holding potential of −70 mV. Representative traces show the mEPSCs in slices treated with saline, DL-AP3 or/and SKF81297. (B) Cumulative
frequency (left) and amplitude (right) histogram of the mEPSCs from the Fmr1 WT mice. (C) Summary of mEPSCs frequency (left) and amplitude
(right) in neurons from the saline, DL-AP3 (10 μM, n = 7 slices/3 mice), SKF81297 (5 μM, n= 6 slices/3 mice), and DL-AP3 (10 μM)+ SKF81297
(5 μM) (n = 7 slices/3 mice). (D) Cumulative frequency (left) and amplitude (right) histogram of the mEPSCs from the Fmr1 KO mice. (E) Summary
of mEPSCs frequency (left) and amplitude (right) in neurons from the saline, DL-AP3 (10 μM, n= 6 slices/3 mice), SKF81297 (5 μM, n = 6 slices/3
mice), and DL-AP3 (10 μM)+ SKF81297 (5 μM) (n = 7 slices/3 mice).
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the Fmr1 KO mice. FMRP interactes with GRK2, and
pharmacological inhibition of GRK2 rescues D1 receptor sig-
naling in Fmr1 KO neurons [31]. D1 receptors can be phos-
phorylated by GRKs [36]. We found that GRK2 levels were
increased in the cell membrane but decreased in the cytosol
in the culture neurons from Fmr1 KOmice (Figure 6A). Syn-
ergistic addition of DL-AP3 (10 μM) and SKF81297 (5 μM)
reversed redistribution of GRK2 between membrane and
cytosol in Fmr1 KO neurons (Figure 6B). Consistently, syner-
gistic addition of DL-AP3 (10 μM) and SKF81297 (5 μM)
reduced the increase of D1 receptor phosphorylation at
serine sites to a level similar to WT neurons (Figure 6C).
Treatment of SKF81297 (5 μM) alone did not reduce the
level of D1 receptor phosphorylation (data not shown). These
data implied that inhibition of Grp1 mGluRs reversed redis-
tribution of GRK2 and decreased the D1 receptor phosphor-
ylation at serine sites.D1 receptor, mGluR5, and NMDARs expression in the PFC
cultures
To further explore the synaptic mechanisms behind the
impairment of dopaminergic modulation of LTP, we
examined the expression of mGluR5 and D1 receptor in
the ACC from WT and Fmr1KO mice. Even though the
level of D1 receptor phosphorylation was increased, the
total D1 expression was not changed in the Fmr1 KO
mice (Figure 7A). There were no difference in the levels
of mGluR5, NMDA receptor NR2A subunit, and NR2B
subunit between the WT and Fmr1 KO mice (Figure 7A
and 7B). Thus, the impairment of mGluR5 and D1 re-
ceptor modulation of synaptic potentiation is not due to
defect in levels of mGluR5, D1 receptor, and NR2A- or
NR2B- containing NMDA receptor.
The function of NMDARs is regulated by its phos-
phorylation. Given that tyrosine phosphorylation of
NMDARs contributes to LTP [43,44], we examined the
Figure 5 Expression of GluR1 in cultured cortical neurons. (A) Representatives of western blot to detect the total expression of AMPA
receptor GluR1 subunit. (B) Total expression of GluR1 was increased after treatment with SKF81297 (5 μM) alone or combining with DL-AP3
(10 μM) in the neurons form Fmr1 WT mice (n = 4 dishes). (C) Representatives of western blot to detect the surface expression of AMPA receptor
GluR1 subunit. (D) Surface expression of GluR1 was increased after treatment with SKF81297 (5 μM) alone or combining with DL-AP3 (10 μM) in
neurons from Fmr1 WT and KO mice. (E) Forskolin (10 μM) alone or combining with DL-AP3 (10 μM) increased the total expression levels of
GluR1 in the cultures from Fmr1 WT mice but not from KO mice. (F) Surface expression of GluR1 was increased after treatment with forskolin
(10 μM) alone or combining with DL-AP3 (10 μM) in neurons from Fmr1 WT and KO mice. n = 4 dishes. *p< 0.05, **p< 0.01 compared with
control; #p< 0.05, ##p< 0.01 compared between Fmr1 WT and KO mice; &p< 0.05 compared between the neurons treated with SKF81297 and
DL-AP3+ SKF81297 in Fmr1 KO mice.
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anti-phosphotyrosine antibody to determine whether or
not NMDARs are phosphorylated to SKF81297 and DL-
AP3. We found that the presence of SKF81297 (5 μM)
alone or SKF81297 (5 μM) plus DL-AP3 (10 μM) did not
affect total NR2A or NR2B subunit expression in the cul-
tures from Fmr1 WT and KO mice (Figure 7B). However,
SKF81297 (5 μM) alone or SKF81297 (5 μM) plus DL-AP3
(10 μM) significantly increased the level of phosphorylationof the NR2B subunit at Tyr-1472 (p-NR2B-Tyr1472) in the
cultures from Fmr1 WT mice (Figure 7C). Meanwhile,
SKF81297 (5 μM) alone failed to increase p-NR2B-Tyr1472
in the cultures from Fmr1 KO mice. Synergistic addition of
DL-AP3 (10 μM) rescued the p-NR2B-Tyr1472 by
SKF81297 (5 μM) in the cultures from Fmr1 KO mice
(Figure 7D). These data implied that the increase of p-
NR2B-Tyr1472 contributed to the surface expression of
GluR1 by SKF81297 and DL-AP3 in the KO cultures.
Figure 6 Expression of GRK2 and D1 receptor phosphorylation. Expression levels of GRK2 were decreased in cytosol preparation (A) and
increased in membrane preparation (B) from the cultures of Fmr1 KO mice as compared with KO neurons. Synergistic addition of DL-AP3 (10 μM)
and SKF81297 (5 μM) reversed redistribution of GRK2 between membrane and cytosol in Fmr1 KO neurons. (C) Synergistic addition of DL-AP3
(10 μM) and SKF81297 (5 μM) reduced the increase of D1 receptor phosphorylation at serine sites to a level similar to WT neurons. n = 4 dishes.
*p< 0.05, **p< 0.01 compared between Fmr1 WT and KO neurons; #p< 0.05 compared with KO control.
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behavior of Fmr1 KO mice
Fragile X patients and animal models exhibit behavioral
phenotypes that are consistent with deficits in PFC func-
tion, such as hyperactivity, anxiety, and learning abnor-
malities (Bear et al., 2004; Moon et al., 2006; Ventura
et al., 2004). We analyzed locomotor activity, anxiety,Figure 7 Expression of D1 receptor, mGluR5, and glutamate receptor
cortex of Fmr1 WT and KO mice. (B) There were no differences in expressio
Fmr1 KO mice ACC. n = 4 mice per group. (C) Representatives of western b
(p-NR2B-Tyr1472). (D) Level of p-NR2B-Tyr1472 was increased after treatme
neurons from Fmr1 WT and KO mice. n = 4 dishes. *p< 0.05, **p< 0.01 com
mice.and learning abilities to characterize hyperactivity and
learning deficit, the common phenotypes in fragile X syn-
drome. We found increased locomotor activity in Fmr1
KO mice (Figure 8A), which was consistent with the our
previous study [31]. The locomotor activity was not
affected following SKF81297 (1 mg/kg) or/and DL-AP3
(4 mg/kg) subcutaneous injection after forty-five minutessubunits. (A) Representatives of western blot from the prefrontal
ns of D1 receptor, mGluR5, NR2A, and NR2B between the WT and
lot to detect the level of phosphorylation of NR2B subunit at Tyr-1472
nt with SKF81297 (5 μM) alone or combining with DL-AP3 (10 μM) in
pared with control; #p< 0.05 compared between Fmr1 WT and KO
Figure 8 Effect of simultaneous treatments on behavior in Fmr1 KO mice. (A) Sample traces of locomotor activity in the open-field test for
control, SKF81297, or/and DL-AP3 injected WT or Fmr1 KO mice, respectively. (B) Fmr1 KO mice traveled more than WT mice at basal condition
(n = 7 mice for WT, n = 7 mice for Fmr1 KO). SKF81297 (1 mg/kg body weight, injected subcutaneously) significantly reduced the distance traveled
by Fmr1 KO mice (n = 6 mice for control, n = 8 mice for SKF81297). DL-AP3 (4 mg/kg) did not affect locomotor activity in Fmr1 KO mice; however,
DL-AP3 combining SKF81297 significantly reduced the distance traveled in a larger scale as compared with the SKF81297 injection alone (n = 7
mice). SKF81297 or/and DL-AP3 did not affect locomotor activity in WT mice. (C) Time in the open arms had no differences between Fmr1 KO
and WT mice in the mice treated with SKF81297 (1 mg/kg) alone or plus DL-AP3 (4 mg/kg). (D) Open arm entries had no differences between
Fmr1 KO and WT mice in the mice treated with SKF81297 (1 mg/kg) alone or plus DL-AP3 (4 mg/kg). N = 6 mice in each group. (E) Simultaneous
treatment of SKF81297 (1 mg/kg) alone or plus DL-AP3 (4 mg/kg) reduced the swim latency on the final day in the Fmr1 KO mice. N = 6 mice in
each group. *p< 0.05, **p< 0.01 compared with Fmr1 WT mice. #p< 0.05 compared between the mice treated with SKF81297 and DL-
AP3+ SKF81297 in Fmr1 KO mice.
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receptor agonist SKF81297 or simultaneous treatment of
SKF81297 and DL-AP3 significantly reduced the distance
traveled by Fmr1 KO mice (Figure 8B). These data indi-
cate that Fmr1 KO mice exhibit hyperactivity and that
simultaneous treatment of D1 agonist and Grp1 mGluRs
antagonist can reduce the hyperactivity phenotype.
We then investigated anxiety-like behaviors with the ele-
vated plus-maze test. We found no differences between
Fmr1 KO and WT mice and no effect of SKF81297
(1 mg/kg) alone or plus DL-AP3 (4 mg/kg) (Figure 8Cand Figure 8D). These data indicate that anxiety-like beha-
viors are not detectable in this fragile X mouse model and
suggest that these behaviors are probably not related to
the D1 receptor signaling pathway. These findings are
consistent with our previous study [31].
Last, the learning ability was detected in the Morris
Water Maze test. Mice were treated with SKF81297
(1 mg/kg i.p.) alone or plus DL-AP3 (4 mg/kg i.p.) for
5 weeks. Swim latency was compared over the 4 days of
the experiment, and there were significant differences in
escape latency between genotype at day 1. SKF81297 or
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tency in the Fmr1 WT and KO mice. Simultaneous
treatment of SKF81297 or DL-AP3 also did not improve
the learning ability in the Fmr1 WT mice. However,
Simultaneous treatment of SKF81297 and DL-AP3
reduced the swim latency on the final day in the Fmr1
KO mice (Figure 8E). Moreover, we compared the swim-
ming speed during the water maze test and found no
differences among the groups (data not shown). These
findings clearly show that simultaneous treatment of
SKF81297 and DL-AP3 significantly improves the spatial
leaning of Fmr1 KO mice.
Discussion
In present study, we have clearly demonstrated that pre-
frontal LTP in slices from Fmr1 knock-out mice is se-
verely attenuated compared with LTP in slices from
Fmr1 WT mice. Although a previous study has shown a
strong reduction in neocortical LTP, the nature of this
decrease was not tested [11]. Here, we first showed that
inhibition of Grp1 mGluRs rescued LTP facilitation by
D1 receptor in Fmr1 KO mice, without effects on basal
synaptic transmission. Then, using the culture systems
we found that Grp1 mGluR inhibition enhanced the
GluR1-subtype AMPA receptors surface insertion by D1
activation in the cortical neurons from Fmr1 KO mice.
Last, behavioral tests indicated that simultaneous treat-
ment of D1 agonist and Grp1 mGluRs antagonist could
reduce the hyperactivity phenotype of Fmr1KO mice.
Exaggerated signaling by grp 1 mGluRs in the FXS
Recent progress in the study of the mouse model of Fra-
gile X has led to a theory that the absence of FMRP leads
to misregulation of protein synthesis at the synapse that
occurs in response to mGluR activity [9,10]. An increase
in mGluR5-mediated activity leads to an increased LTD of
synaptic activity in the Fmr1KO mice. Exaggerated trans-
lation linked to Grp 1 mGluRs, i.e. overactive signaling by
Grp 1 mGluRs, could contribute to slowed synaptic devel-
opment and other symptoms of FXS [9,10]. Our previous
study has shown a strong reduction of LTP in the pre-
frontal cortex [11], a structure involving in higher brain
functions such as learning and memory, drug addiction,
and attention (Courtney et al., 1998; Frankland et al.,
2004; Zhao et al., 2005b; Zhuo, 2002, 2008). In the present
study, we found that low dose of mGluR1 antagonist DL-
AP3 did not affect the LTP induction in the prefrontal
cortex and the AMPA surface trafficking in the culture
neurons. However, this weak inhibition of Grp 1 mGluRs
could rescue the synaptic plasticity mediated by dopamine
receptor. This finding suggests a complex relationship be-
tween mGluRs and dopamine receptors. The therapeutic
window for mGluR1 antagonists may be narrow because
mGluR1 is essential for normal cerebellar function.Dopaminergic modulation of long-term synaptic plasticity
In the prefrontal cortex, including the ACC, activation
of the NR2B and NR2A subunits of the NMDA receptor
is critical for the induction of cingulate long-term synap-
tic plasticity [45-47]. Dopamine D1 receptor regulates
NMDA receptor functions by direct protein-protein
interactions [48,49]. D1 receptor activation has been
reported to increase the surface expression of AMPA
receptors and facilitate their synaptic insertion in the
cultured neurons [26,50,51]. The surface expression of
AMPA receptors correlates with their synaptic insertion
[50-52]. In the present study, we found that D1 recep-
tors facilitated cingulate prefrontal LTP through increas-
ing synaptic incorporation of homomer GluR1 in the
Fmr1 WT mice. However, the plasticity and the increase
of GluR1 surface expression induced by stimulating D1
receptor was significantly attenuated in Fmr1 KO neu-
rons. This indicates that silence of Fmr1 gene plays as a
key role in the deficits of DA-mediated modulation of
excitatory transmission in forebrain neurons [31].
Adenylyl cyclase activation and synaptic plasticity in the
FXS
It is reported that patients with FXS show abnormal
function or regulation of the catalytic subunit of adenyl-
ate cyclase. They found that in patients with FXS basal
production of cAMP was 63% of that of control subjects
[53]. Our previous study reports that D1 receptor signal-
ing was impaired, i.e., the increase in cAMP caused by
SKF81297 was attenuated, accompanied by D1 receptor
hyperphosphorylation at serine sites in the PFC of Fmr1
KO mice [31]. In the present study, we found that simul-
taneous application of adenylyl cyclase activator forsko-
lin with DL-AP3 could partially rescued LTP in the
Fmr1 KO mice (Figure 2C and 2F) in the slices record-
ing. Consistent with this result, surface expression of
GluR1 was increased after simultaneous treatment of
forskolin (10 μM) and DL-AP3 (10 μM) in the cultures
from Fmr1 KO mice (Figure 5F). These findings suggest
that activation of adenylyl cyclase by forskolin or D1 re-
ceptor is a potential therapy strategy for the FXS.
Grp 1 mGluRs, D1 modulation of AMPA receptors, and
synaptic Potentiation
Here, we found that the decreased LTP in the prefrontal
cortex observed in Fmr1 KO mice correlates with
decreased surface levels of GluR1 expression. Our
present recordings from the adult brain slice revealed
that D1 receptors facilitated cingulate prefrontal LTP
through increasing synaptic incorporation of homomer
GluR1, even though low dose of mGluR1 antagonist DL-
AP3 did not affect the LTP induction in the prefrontal
cortex and the AMPA surface trafficking in the culture
neurons. Unaltered PPF suggests that inhibition of Grp
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by D1 receptor in a postsynaptic manner. However, we
cannot rule out the possible presynaptic modulation of
inhibitory transmission by dopamine receptor and Grp 1
mGluRs [54,55], since inhibitory transmission was
blocked in our recordings. We failed to find consistent
D1 modulation of basal AMPA receptor transmission in
adult slice recordings [56], while in cultured PFC neurons,
D1 receptor activation caused GluR1 subunit surface ex-
pression and synaptic insertion. The inconsistency between
adult slices and cultured neurons could be explained by de-
velopmental differences (cultured neurons are liable to ex-
press proteins that may not be expressed in vivo) or the
differences between in vivo and in vitro neuronal networks
[57-60].
GRK2 and D1 receptor hyperphosphorylation in the FXS
G-protein coupled receptors can be desensitized follow-
ing activation by agonists by becoming phosphorylated
by members of the family of G protein-coupled receptor
kinases (GRKs). Phosphorylated receptors are then
bound by arrestins, which prevent further stimulation of
G proteins and downstream signaling pathways [36].
Our present and previous studies show that D1 receptor
signaling is impaired, accompanied by D1 receptor
hyperphosphorylation at serine sites and subcellular re-
distribution of G protein-coupled receptor kinase 2
(GRK2) in the prefrontal cortex of the Fmr1 KO mice.
Synergistic application of DL-AP3 and SKF81297 could
reverse redistribution of GRK2 between membrane and
cytosol in Fmr1 KO neurons and further reduce the in-
crease of D1 receptor phosphorylation at serine sites to
a level similar to WT neurons. These results suggest that
D1 receptor hyperphosphorylation might be caused by
the subcellular redistribution of GRK2 in the Fmr1 KO
mice and that inhibition of Grp1 mGluRs might modulate
the subcellular distribution of GRK2. These data implied
that inhibition of Grp1 mGluRs reversed redistribution of
GRK2 and decreased the D1 receptor phosphorylation at
serine sites. Thus, inhibition of Grp1 mGluRs can recover
the capability of D1 receptor to activate G proteins and
downstream signaling pathways.
NMDA receptor and synaptic transmission in Fmr1 KO
mice
In addition, there is no difference in D1 receptor,
mGluR5, NR2A, and NR2B expression between Fmr1
KO and WT mice as shown by western blot. The results
suggest that the impairment of mGluR5 and D1 receptor
facilitation of LTP in prefrontal cortex of Fmr1 KO mice
is not due to defect in levels of mGluR5, D1 receptor,
and NR2A- or NR2B- containing NMDA receptor. The
function of NMDARs is regulated by its phosphorylation
and tyrosine phosphorylation of NMDARs is thought tocontribute to LTP [43,44]. In this study, we found that
activation of D1 significantly increased the level of phos-
phorylation of NR2B subunit at Tyr-1472 (p-NR2B-
Tyr1472) in the cultures from Fmr1 WT mice but not in
the cultures from Fmr1 KO mice. Synergistic inhibition
of Grp1 mGluR could rescue the p-NR2B-Tyr1472 by
D1 receptor in the cultures from Fmr1 KO mice. Thus,
the increase of phosphorylation of NMDARs by Grp1
mGluR antagonist may contribute to the improvement
of surface expression of GluR1 and synaptic plasticity by
D1 activation in the Fmr1 KO mice.
In summary, the present study, together with our pre-
vious study, reveals that mGluR1 inhibition is a useful
strategy to recover D1 receptor signaling in the Fmr1KO
mice, and that combination of Grp1 mGluR antagonist
and D1 agonist is a potential drug therapy for the FXS.
Materials and methods
Animal
Male mice aged 5 to 6 weeks were used for behavioral
experiments and brain slice recordings. Fmr1 KO mice
(strain name: FVB.129P2-Fmr1tm1Cgr/J; stock #:4624) and
control wild-type (WT) mice on the same strain back-
ground (stock # 4828) were purchased from The Jackson
Laboratory (Genetics Research, Bar Harbor, Maine, USA)
and bred in the animal facility of the Fourth Military
Medical University. All mice were housed in plastic boxes
in groups of 4 under a 12:12 light cycle; food and water
were provided ad libitum. The use of animals was
reviewed and approved by the Institutional Ethical Com-
mittee of the Fourth Military Medical University.
Slice preparation
Coronal prefrontal brain slices (300 μM) from Fmr1 WT
and KO mice, containing the anterior cingulate cortex
(ACC), were prepared using standard methods [45]. Slices
were transferred to submerged recovery chamber with
oxygenated (95% O2 and 5% CO2) artificial cerebrospinal
fluid (ACSF) containing (in mM: 124 NaCl, 2.5 KCl, 2
CaCl2, 1 MgSO4, 25 NaHCO3, 1 NaH2PO4, 10 glucose) at
room temperature for at least 1 h.
Whole-cell recordings
Experiments were performed in a recording chamber on
the stage of an Axioskop 2FS microscope with infrared
DIC optics for the visualization of whole-cell patch
clamp recording. In the ACC layer II to III, pyramidal
neurons have been reported as the major locations of
intra-cortical horizontal pathways [61]. The superficial
layers of the ACC receive substantial glutamate input [62].
In the present study, we recorded excitatory postsynaptic
currents (EPSCs) from neurons in layer II to III induced
by the stimulation of layer V. AMPA receptor (AMPAR)-
mediated EPSCs were induced by repetitive stimulations
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We identified pyramidal neurons by injecting depolarized
currents into neurons to induce action potentials. The
typical firing pattern of a pyramidal neuron showed sig-
nificant firing frequency adaptation, whereas the pattern
in an interneuron showed fast-spiking action potentials
followed by pronounced hyperpolarization. After obtain-
ing stable EPSCs for at least 10 min, LTP was induced by
80 pulses at 2 Hz, and then paired with postsynaptic
depolarization at + 30 mV (i.e., “pairing training”). In cal-
culating the LTP amplitude, the last 5 min recordings
(6 EPSCs) before the pairing training were averaged
as the baseline. The last 5 min recordings (6 EPSCs)
before the ending were also averaged in order to analyze
the changes of LTP. The recording pipettes (3 to 5 MΩ)
were filled with solution containing (mM) 145 K-gluconate,
5 NaCl, 1 MgCl2, 0.2 EGTA, 10 HEPES, 2 Mg-ATP, and 0.1
Na3-GTP (adjusted to pH 7.2 with KOH). Picrotoxin
(100 μM) was always present to block GABAA receptor-
mediated inhibitory synaptic currents. To record the
mEPSCs, 0.5 μM Tetrodotoxin (TTX) was added into the
bath solution. The access resistance was 15 to 30 MΩ,
which was monitored throughout the experiment. Data
were discarded if access resistance changed by over 15%
during an experiment.
Primary culture of prefrontal cortical neurons
Primary cultures of prefrontal cortical neurons were pre-
pared from embryonic 18 days old (E18) Sprague–Dawley
rats as described previously [31]. Serum-free B27/neuro-
basal medium (Invitrogen, Carlsbad, USA CA) was used
to prevent glial cell growth which is reduced to less than
0.5% of the nearly pure neuronal population, as judged by
immunocytochemistry for glial fibrillary acidic protein and
neuron-specific enolase [63]. Cells were seeded at the
density of 3 ~ 4× 103 cells/cm2 onto 24-well plates coated
with 50 μg/ml poly-D-lysine (Sigma, St. Louis, MO). The
cultures were incubated at 37°C in 95% air, 5% CO2 with
95% humidity. Half of the medium was replaced every
4 days. Cultures were used for experiments between 10
and 14 days in vitro (DIV). SKF81297 (5 μM), DL-AP3
(10 μM), and forskolin (5 μM) were added in the culture
medium for 24 h before the cells were harvested.
Western blot analysis
Western blot analysis was performed as described previ-
ously [31]. Equal amounts of protein (50 μg) from the
cultures were separated and electrotransferred onto
PDVF membranes (Invitrogen), which were probed with
antibodies for mGluR5 (1:500, Abcam, Cambridge, MA),
GluR1 (1:300, Abcam), NR2A (1:200, Millipore), NR2B
(1:1000, Millipore), p-NR2B Tyr1472 (1:1000, Cell sig-
naling), GRK2 (1:1000, Santa Cruz), D1 receptor (1:1000,
Millipore), FMRP (1:1000, Millipore), anti-phosphoserineof D1 receptor (1:2500, BD Biosciences), with β-actin
(1:10000, Sigma) or cadherin (1:2000, Sigma) as loading
control. For data quantitation, band intensity was
expressed relative to the loading control (β-actin or cad-
herin). The membranes were incubated with horseradish
peroxidase conjugated secondary antibodies (anti-rabbit/
anti-mouse IgG for the primary antibodies), and bands
were visualized using an ECL system (Perkin Elmer).
Surface biotinylation assay
Surface protein samples were detected through a biotiny-
lation assay, followed by Western blot analysis with the
antibodies as previously described [31]. Cell monolayers
were washed and incubated in sulfo-NHS-LC-biotin
(0.3 mg/ml in cold PBS; Pierce, Rockford, IL) for 30 min.
Surface biotinylation was stopped by removing the solu-
tion, followed by incubation in 10 mM ice-cold glycine in
PBS for 20 min. Cells were washed thrice with cold PBS
and lysed by RIPA buffer containing (mM) 20 HEPES
pH 7.4, 100 NaCl, 1 EGTA, 1 Na3VO4, 50 NaF, 1 mM
4-(2-aminoethyl)-benzenesulfonylfluoride hydrochloride,
plus 1% NP-40,1% deoxycholate, 0.1%SDS, 10 mg/ml leu-
peptin, and 1 mg/ml aprotinin. Biotinylated proteins were
precipitated with 100 ml of ImmunoPure Immobilized
Streptavidin (Pierce, Rockford, IL), separated on 4% to
12% SDS-PAGE gels, and transferred to polyvinylidene
fluoride membranes. The membranes were probed with
anti-GluR1. The membranes were incubated with horse-
radish peroxidase-conjugated secondary antibodies (anti-
rabbit/anti-mouse IgG for the primary antibodies), and
bands were visualized using an ECL system (Perkin Elmer).
Locomotor activity
Horizontal locomotor activity was conducted, as
described in the report [64], with an open-field (OP) test
system (Jiangliang, Shanghai, China). The open field was
a square arena (30 cm× 30 cm× 30 cm) with clear Plexi-
glas walls and floor, and then placed inside an isolation
chamber with dim illumination and a fan. Mice were
placed in the center of the box, allowed to freely explore
for 10 min, and videotaped using a camera fixed above
the floor and then analyzed with a video-tracking sys-
tem. Forty-five minutes after the subcutaneous injection
of saline, DL-AP3, and/or SKF81297, each subject was
placed in the center of the open field, and its activity
was measured for 30 min.
Elevated plus maze
The Elevated Plus Maze (EPM) was conducted as
described in the report [64]. The apparatus comprised of
two open arms (25 × 8 × 0.5 cm) and two closed arms
(25 × 8 × 12 cm) that extended from a common central
platform (8 × 8 cm). The apparatus elevated to a height
of 50 cm above the floor. Mice were allowed to habituate
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treated with gentle handling two times per day to eliminate
their nervousness. For each test, individual animals were
placed in the center square, facing an open arm, and allowed
to move freely for 5 min. Mice were videotaped using a cam-
era fixed above the maze and analyzed with a video-tracking
system. Open and closed arm entries (all four paws in an
arm) were scored by an experienced observer. The number
of entries and time spent in each arm were recorded.
Morris water maze test
In the Morris Water Maze test, mice were treated either
with SKF81297 (1 mg/kg i.p.) alone or with SKF81297
plus DL-AP3 (4 mg/kg i.p.) for 5 weeks. The experi-
ments were conducted as described previously [65]. The
maze was made of white opaque plastic with a diameter
of 120 cm and 40 cm high walls, which was filled with
water at 25°C to avoid hypothermia. A small escape
platform (diameter = 10 cm) was placed at a fixed pos-
ition in the center of one quadrant 25 cm from the per-
imeter and was hidden 1 cm beneath the water surface.
The room contained a number of fixed visual cues on
the walls. The acquisition trial phase consisted of 4
training days (days 1 to 4), with 2 trials per day and a
15-min inter-trial intervals. Four points equally spaced
along the circumference of the pool (north, south, east,
and west) served as the starting positions, which were
randomized across the four trials each day. If an animal
did not reach the platform within 90 s, it was guided to
the platform, where it had to remain for 30 s before
being returned to its home cage. Mice were kept dry be-
tween trials in a plastic holding cage filled with paper
towels. Starting locations were changed every trial. The
results of four trials were averaged and used in the data
analysis. The time required to escape onto the hidden
platform was recorded as escape latency.
Data analysis
Results were expressed as mean ± SEM. Statistical com-
parisons were performed by one-way analysis of variance
(ANOVA) using the post-hoc comparisons with Tukey's
test. In all cases, p< 0.05 was considered statistically
significant.
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